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mainly caused by pathogenic variants in over 10 
loci, with MYBPC3, MYH7 and TNNT2 account‑
ing for approximately 50% of the HCM families 
and encoding cardiac myosin ‑binding protein C, 
β ‑myosin heavy chain, and cardiac troponin T, re‑
spectively.2 Other inheritable causes of the dis‑
ease include pathogenic variants in genes encod‑
ing proteins involved in calcium handling and for 
proteins of the Z ‑disk.3 Most of the pathogenic 
variants found in HCM genes are missense and 
INTRODUCTION Hypertrophic cardiomyopathy 
(HCM) is a cardiac disease characterized by left 
ventricular hypertrophy (thickness ≥15 mm) un‑
explained by secondary causes, and a nondilated 
left ventricle with preserved or increased ejection 
fraction. It is an important cause of sudden car‑
diac death, and its prevalence has been estimated 
at approximately 1/500 individuals in the adult 
population.1 Hypertrophic cardiomyopathy is 
considered a disease of the cardiac sarcomere 
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ABSTRACT
INTRODUCTION Hypertrophic cardiomyopathy (HCM) is a heart disorder caused by autosomal dominant 
alterations affecting both sarcomeric genes and other nonsarcomeric loci in a minority of cases. However, 
in some patients, the occurrence of the causal pathogenic variant or variants in homozygosity, compound 
heterozygosity, or double heterozygosity has also been described. Most of the HCM pathogenic variants 
are missense and unique, but truncating mutations of the MYBPC3 gene have been reported as founder 
pathogenic variants in populations from Finland, France, Japan, Iceland, Italy, and the Netherlands.
OBJECTIVES This study aimed to assess the genetic background of HCM in a cohort of Polish patients.
PATIENTS AND METHODS Twenty ‑nine Polish patients were analyzed by a next ‑generation sequencing 
panel including 404 cardiovascular genes.
RESULTS Pathogenic variants were found in 41% of the patients, with ultra ‑rare MYBPC3 c.2541C>G 
(p.Tyr847Ter) mutation standing for a variant hotspot and correlating with a lower age at HCM diagnosis. 
Among the nonsarcomeric genes, the CSRP3 mutation was found in a single case carrying the novel 
c.364C>T (p.Arg122Ter) variant in homozygosity. With this finding, the total number of known HCM 
cases with human CSRP3 knockout cases has reached 3.
CONCLUSIONS This report expands the mutational spectrum and the inheritance pattern of HCM.
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known HCM cases with null homozygous altera‑
tions in this gene has increased to 3.
PATIENTS AND METHODS Patients Twenty ‑nine 
unrelated patients were selected from those at‑
tending an outpatient service dedicated to the di‑
agnosis and management of HCM at the Institute 
of Cardiology, John Paul II Hospital (Kraków, Po‑
land). Patients underwent clinical history tak‑
ing, physical examination, electrocardiography 
(ECG), echocardiography, cardiopulmonary ex‑
ercise test coupled with ambulatory ECG mon‑
itoring, and cardiac magnetic resonance imag‑
ing. Diagnostic criteria for HCM were defined in 
adults by a maximal left ventricular wall thick‑
ness of 15 mm or higher on echocardiography, 
or of 13 mm or higher in relatives, in the absence 
of loading conditions.16 Family history of sudden 
cardiac death, syncope episodes, and the presence 
of nonsustained ventricular tachycardia were de‑
fined as described by O’Mahony et al.17 Electro‑
cardiographic abnormalities that were consid‑
ered of clinical significance included abnormal 
Q waves (0.04 s or 25% depth of the R wave), 
left ventricular hypertrophy (voltage criteria), 
and marked repolarization changes (eg, T ‑wave 
inversion in at least 2 leads). Familial HCM cases 
were defined if at least 1 additional affected fam‑
ily member with HCM or 1 case of sudden cardi‑
ac death was present in the pedigree. When avail‑
able, the relatives of index cases were recruited for 
genetic testing. All patients gave informed con‑
sent for the DNA analyses, and the study was ap‑
proved by local ethics committees in accordance 
with the principles of the Declaration of Helsinki.
Genetic analyses Genomic DNA from peripheral 
blood was tested by NGS with the Ion AmpliSeq™ 
Cardiovascular Research Panel (ThermoFisher, 
Carlsbad, California, United States), including 
the 16 “core HCM genes” defined by the Amer‑
ican College of Medical Genetics and Genom‑
ics (ACMG),18 as well as other 388 genes known 
to harbor alterations affecting cardiovascular 
functioning (Supplementary material, Table S1). 
The Ion Chef System (ThermoFisher) was em‑
ployed for the automated library and template 
preparation, as well as for chip loading. Sequenc‑
ing reactions were carried out on the Ion S5 XL 
System (ThermoFisher). Sequencing reads were 
aligned on the GRCh37/hg19 reference sequence 
by the Torrent Suite Software v.5.4.0 (Thermo‑
Fisher). For every patient, the panel coverage as 
well as the mean and median read depth reached 
for each of 404 genes is given in Supplementa‑
ry material, Table S1. The mapped reads were an‑
alyzed to determine the presence of DNA point 
variants by Variant Caller v5.4.0.46 plugin using 
“germline – low stringency” parameters (Ther‑
moFisher). Variants’ calls were scored and pri‑
oritized by the TGex software (LifeMap Scienc‑
es, Alameda, California, United States; http://
tgex.genecards.org/), which ranks variants ac‑
cording to their association to the phenotype (ie, 
unique or private within families.2 These altera‑
tions are believed to have a dominant negative 
effect, acting as a “poison polypeptide” on sar‑
comere function.4 The only exception is MYB-
PC3, in which about two ‑thirds of pathogenic 
variants are truncating and haploinsufficiency 
is postulated as a pathogenetic mechanism of 
the disease.5 To date, at least 12 different trun‑
cating MYBPC3 pathogenic mutations have been 
reported as founder variants in populations from 
Finland, France, Japan, Iceland, Italy, Spain, and 
the Netherlands.5-8
In most adolescents and adults, HCM is inher‑
ited as an autosomal dominant trait with a clinical 
outcome characterized by incomplete penetrance 
and variable expression. The disease phenotype 
can indeed be modulated by environmental fac‑
tors, by the genetic context (including polymor‑
phisms of the renin–angiotensin system [RAS]),9 
and by the occurrence of the causal pathogenic 
variant or variants in homozygosity, compound 
heterozygosity, or double heterozygosity.10 Janin 
et al11 have recently reported 2 unrelated kindreds 
with homozygous truncating variants in the cys‑
teine and glycine ‑rich protein 3 (CSRP3) gene en‑
coding a member of the CSRP family of muscle 
LIM protein (MLP).
It is likely that HCM individuals are un‑
derdiagnosed,12 especially in countries where 
the availability of genetic testing based on next‑
‑generation sequencing (NGS) is limited. Consid‑
ering the prevalence of HCM, the estimated num‑
ber of HCM patients in Poland is approximate‑
ly 78 000. Until now, only single reports describ‑
ing genetic causes of HCM in Polish patients have 
been reported.13-15 Therefore, the aim of the cur‑
rent study was to assess the genetic background 
of HCM in a cohort of patients from the south‑
‑eastern part of Poland, analyzed by an NGS pan‑
el including 404 genes known to harbor altera‑
tions affecting cardiovascular system function. 
Thanks to this approach, we could identify a MYB-
PC3 truncating alteration that could represent 
a novel Polish founder MYBPC3 pathogenic vari‑
ant. Also, we detected a new patient with the ho‑
mozygous CSRP3 variant; thus, the number of 
WHAT’S NEW?
Most of the DNA mutations leading to hypertrophic cardiomyopathy (HCM) 
are inherited with an autosomal dominant pattern and are unique or seen in 
a limited number of families. However, in some ethnic groups, founder muta‑
tions have been described. We report the analysis of 404 genes in a cohort 
of 29 Polish patients affected by HCM. Our results showed that an ultra ‑rare 
alteration in the MYBPC3 gene, absent in databases from large ‑scale se‑
quencing projects, was a mutation hotspot in the present Polish cohort and 
could represent a novel founder pathogenic variant. Moreover, we found that 
1 patient was homozygous for a novel truncating mutation in the CSRP3 gene, 
thus increasing the number of known human CSRP3 knockout cases to 3. This 
finding also suggests that the autosomal recessive inheritance pattern could 
be more frequent in HCM than reported thus far.
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patient, the clinical and molecular data were tab‑
ulated (FIGURE 1). Phenotype data were present‑
ed as continuous variables obtained from clin‑
ical data and instrumental measurements, and 
they were summarized using means and stan‑
dard deviations. The mean values of age at diag‑
nosis, maximal wall thickness, and left ventricu‑
lar mass were compared using the t test for inde‑
pendent data between the subgroups of patients 
with different genotypes. Also, associations be‑
tween sex, the genotype of 2 polymorphisms in 
the genes of the RAS, and clinical features were 
tested. The penetrance of HCM, according to age 
at diagnosis, was analyzed by the Kaplan–Meier 
method, and differences between cumulative haz‑
ard were evaluated with the log ‑rank test. Due to 
the relatively low number of patients, no adjust‑
ments were planned for multiple testing. There‑
fore, the analysis is exploratory and the results 
should be considered as hypothesis generating.
RESULTS AND DISCUSSION In total, 12 of the 29 
patients (41%) were found to carry at  least 
1 pathogenetic, likely pathogenetic, or VUS‑
‑favoring pathogenic alteration of the “core HCM 
genes,” as classified by the 2015 ACMG/AMP 
guidelines and ClinVar database (TABLE 1 and 
FIGURE 1). Most of the changes were identified in 
the MYBPC3, MYH7 and TNNT2 genes. The gen‑
otype of the rs5186 and rs699 polymorphisms, 
mapping respectively in the angiotensin recep‑
tor type 1 (AGTR1) and angiotensinogen (AGT) 
genes, belonging to the RAS, was also recorded 
(FIGURE 1). Indeed, some studies have shown that 
rs5186 and rs699 may influence the clinical phe‑
notype of HCM,22 since the RAS regulates cardi‑
ac function, blood pressure, and electrolyte ho‑
meostasis.23 However, in the present cohort, no 
significant correlation with the disease expres‑
sion was found.
The identified mutational spectrum includ‑
ed 10 distinct substitutions: 6 missense, 3 non‑
sense, and 1 intronic change. Most of the mis‑
sense variants were sarcomeric, and, among 
them, 3 mapped in MYH7, 2 in MYBPC3, and 1 in 
TNNT2. On the other hand, 2 of the nonsense al‑
terations were found in MYBPC3 and 1 in CSRP3. 
The GnomAD allele frequency of all the sarco‑
meric alterations was smaller than 0.01%, that 
is, the MAF threshold suggested for HCM patho‑
genic variants.24
A single variant was found in more than 1 pa‑
tient (Supplementary material, Figure S1A). 
The MYBPC3 c.2541C>G variant, resulting 
in the premature insertion of a stop codon in 
exon 24 (p.Tyr847Ter), was indeed identified in 
4 unrelated cases, despite the fact that it is ab‑
sent in the GnomAD. Carriers of the MYBPC3 
c.2541C>G showed a lower age at HCM diagno‑
sis compared with carriers of other DNA vari‑
ants, with a 50% probability of HCM diagnosis 
at 38 years for MYBPC3 c.2541C>G carriers, in 
comparison with the age of 49 years for the car‑
riers of other DNA variants (P = 0.04; FIGURE 2). 
HCM). Between the variants scored by TGex and 
matching with the HCM phenotype, only the ones 
meeting all the following parameters were fil‑
tered: 1) nonsynonymous exonic or ±10 ‑bp in‑
tronic variants; 2) minor allele frequency (MAF) 
in the Genome Aggregation Database (GnomAD) 
of less than 0.01; 3) high quality of the call (ie, 
Q&R score = Coverage ≥20 × and GQ ≥50); and 
4) at least 20% of reads showing the alternative 
allele (% Alt >20%). The resulting variants were 
confirmed by Sanger sequencing (polymerase chain 
reaction [PCR] primers are listed in Supplementary 
material, Table S2) and classified into 5 categories 
presented in the 2015 guidelines of the ACMG / As‑
sociation for Molecular Pathology (AMP),19 mod‑
elled by a Bayesian framework as previously de‑
scribed.20 This approach allowed a better categori‑
zation of the DNA variants into 7 classes: 1) patho‑
genic; 2) likely pathogenic; 3) variants of unknown 
significance (VUS)–favoring pathogenic; 4) VUS; 
5) VUS ‑favoring benign; 6) likely benign; and 7) 
benign. Data for this classification were obtained 
from the CardioVai (www.cardioclassifier.org), Car‑
dio Classifier (www.cardiovai.engenome.com), In‑
tervar (www.wintervar.wglab.org), and Varsome 
(www.varsome.com) systems, as well as from the 
ClinVar database (www.ncbi.nlm.nih.gov/clinvar). 
Regarding MYH7, the ACMG/AMP 2015 classifica‑
tion was adapted following the ClinGen’s Inherited 
Cardiomyopathy Expert Panel.21 Variants not yet 
reported in literature were referred to as “novel.”
The presence of copy number alterations en‑
compassing the CSRP3 c.364C>T variant was 
investigated by a  SYBR Green–based quanti‑
tative PCR on an ABI7900 HT Fast Real Time 
PCR System (ThermoFisher), with the follow‑
ing primer pair mapping in the CSRP3 gene: FW‑
‑5’‑TGGGAATTCTGGTTTGCTTTG ‑3’ and Rv ‑5’‑
GAGGCATGTAAGATCCAGTGGTT ‑3’. The exper‑
iment included patient 58 as well as 4 unaffect‑
ed control individuals. The reference gene, TERT, 
was simultaneously quantified in a separate tube 
for each specimen.
MYBPC3 haplotype analysis To test whether 
the carriers of the same MYBPC3 variant share 
a common haplotype, a linkage analysis around 
the MYBPC3 region on chromosome 11 was per‑
formed with 8 microsatellite markers upstream 
the  gene (ie, D11S4109, D11SA1, D11S1784, 
D11S4165, D11S1395, and D11S1765), 6 single 
nucleotide polymorphisms within the gene (ie, 
rs1052373, rs11570078, rs2856650, rs3729989, 
rs11570051, and rs11570050), and 6 microsatel‑
lite markers downstream MYBPC3 (ie, D11S905, 
D11S1763, D11S986, D11S4174, D11S4137, 
D11S1385, D11S1344, and D11S1252). These poly‑
morphic markers cover about 19.8 Mb around 
MYBPC3.
Statistical assessment of genotype–phenotype cor-
relations All statistical analyses were performed 
using the SPSS software package version 20.0 
(IBM SPSS Statistics, Milan, Italy). For each 
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Patient 9a 10 11 12 18 19 22 42 58 64 74 87 106 107 139 161 167 3566 3740a 3868 3937a 4022a 4737
Sex M M F M F M F M F F M M F M M M F M M F F F M
Age at diagnosis, y 32 38 69 24 13 17 7 61 54 55 38 49 19 5 34 52 66 25 32 28 43 29 42
Family history
NYHA NE II I I I I II II II I II III II I I II II I I I II III I
Cardiac procedures and surgery
Hypertension NE + + + + + + +
Maximal wall thickness
Left ventricular mass NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE
Cardiac MRI areas of contrast + NE NE NE NE NE NE + + NE NE NE + NE
Left ventricular ejection fraction, % NE NE
+ + + + + + + + + + +
QTc NE NE
Brugada-type changes + NE
Conduction abnormalities NE RBBB RBBB LAFB LBBB RBBB
Supraventricular arrhythmias NE NE NE
Nonsustained ventricular tachycardia + + + + +
Syncope/Presyncope + + NE + + + + + +
AMI/NSTEMI +
Maximal oxygen uptake, % NE NE 125 NE NE NE NE NE 53 68 78 NE 75 NE 107 78 NE NE NE NE NE NE –
Diastolic dysfunction, grade II NE I NE NE I III I NE I II I III I NE II II II II
Thoracic pain + NE + + + + + + + + + +
Failure NE + +
AGTR1 rs5186 AC AC AC AA AC AC AC AC AA AA AC AA AA AC AA AA AC AA AC AA AA AA AC
AGT rs699 AA AG AG AG AG AG AA AG AG AA AA AA AG AG AA AG AG AA AG AG AG AA AA
Cardiac procedures and surgeries Maximal wall thickness Supraventricular arrhythmias
Presence of SCD in the family Heart transplant 13–29 mm ≥130 g/mq >50% <300 ms PSVT Heterozygous
Familial HCM Ablation ≥30 mm <130 g/mq <50% 300-450 ms AF Homozygous
Myectomy ≥450 ms SA
Coronary bypass
Intracardiac defibrillator
Pacemaker
Family history Left ventricular mass
II
Left ventricular EF
+
++
+
+
NE
NE
NE
LAFB
NE
NE
NE
M
+
NE
+
+
I
44
NE
57
M
57
14
1
NE
+
218
39
M
III
+
+
39
+
+
+
NE
III III
IV
LBBB
109
M
52
II
NE
49
II
+
+
NE
I
3682a
M
33
II
+
NE
211
M
AA
Clinical 
features
AA ACAG AA AA
DNA variants in 
"core HCM 
genes"
Secondary 
molecular 
findings
RAS AA ACAC AA AA
DNA variants
AG
Obstructive cardiomyopathy (outflow obstruction)
MYBPC3
MYH7
TNNT2
CSRP3
GYG1
GUSB
PMM2
SCO2
QTc 
FIGURE 1 Clinical and molecular data of the 29 Polish cases affected by hypertrophic cardiomyopathy. The x ‑axis shows the 29 patients. The y ‑axis shows the clinical parameters (top), “core HCM genes” (middle), and other 
genes found mutated (bottom). The last 2 rows show the genotype of the rs5186 and rs699 polymorphisms, mapping respectively in the AGTR1 and AGT genes of the renin –angiotensin system. The color code employed in the figure 
is shown at the bottom. 
a   Patient on drug treatment 
Abbreviations: +, present; AF, atrial fibrillation; AMI, acute myocardial infarction; EF, ejection fraction; F, female; LAFB, left anterior fascicular block; LBBB, left bundle branch block; M, male; MRI, magnetic resonance imaging; NE, not 
evaluated; NSTEMI, non–ST ‑segment elevation myocardial infarction; NYHA, New York Heart Association; PSVT, paroxysmal supraventricular tachycardia; RAS, renin–angiotensin system; RBBB, right bundle branch block; SA, sinus arrest 
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TABLE 1 Genetic alterations identified in 12 of the 29 Polish patients affected by hypertrophic cardiomyopathy (for references 51–67, see Supplementary material) (continued on the next page)
Patient Gene Location Ref Alt RefSeq Nucleotide AA Coding 
impact
Zygosity dbSNP GnomAD ‑Exomes allele 
frequency, %
ClinVar ACMG / AMP 2015 ClinVar 
conditions
Comment
European 
Non ‑Finnish
Total Classification Activeted rules
Pt 9 MYBPC3 11:47369975 C T NM_000256.3 c.772G>A Glu258Lys Missense Het rs397516074 0.003 0.001 P, LP P PP2, PP3, PP5, 
PM1, PM2, PS4
HCM Reported in unrelated 
patients with HCM (Niimura 
et al34; Richard et al35; Nanni 
et al36; Van Driest et al37; 
Song et al38; Murphy et al39)
Pt 10 MYBPC3 11:47359003 G C NM_000256.3a c.2541C>Ga Tyr847Tera Nonsense Het rs397515974 0 0 P, LP P PP3, PP5, PM1, 
PM2, PS1, PVS1
HCM Reported in individuals with 
HCM (Van Driest et al37; 
Berge et al40; Kapplinger 
et al41; Viswanathan et al42; 
Zhao et al43)
Pt 18 MYBPC3 11:47369403 C T NM_000256.3 c.821+5G>A – Intronic Het rs397516077 0 0 P, LP P PP3, PP5, PM1, 
PM2, PS1, PVS1
HCM Reported in association with 
HCM (Carrier et al44; Millat 
et al45)
Pt 22 MYBPC3 11:47359003 G C NM_000256.3a c.2541C>Ga Tyr847Tera Nonsense Het rs397515974 0 0 P, LP P PP3, PP5, PM1, 
PM2, PS1, PVS1
HCM Reported in individuals with 
HCM (Van Driest et al37; Berge 
et al40; Kapplinger et al41; 
Viswanathan et al42; Zhao 
et al43)
MYH7 14:23891518 T C NM_000257.3 c.3116A>G Glu1039Gly Missense Het rs199573700 0.004 0.01 VUS VUS ‑3B PP2, PP3, PM2 HCM Novel but present in ClinVar
Pt 57 MYH7 14:23886875 A C NM_000257.3 c.4190T>G Leu1397Arg Missense Het – 0 0 – P PP3, PP5, PM1, 
PM2, PS1, PVS1
– Novel
Pt 58 CSRP3 11:19207813 G A NM_003476.4 c.364C>T Arg122Ter Nonsense Hom rs902082118 0 0.001 LP P PP2, PP3, PM2, 
PVS1
Not assessed Novel
Pt 64 MYBPC3 11:47364270 G A NM_000256.3 c.1483C>T Arg495Trp Missense Het rs397515905 0 0 P/VUS LP PP2, PP3, PM1, 
PM2, PM5
HCM Reported in at least 
4 individuals with HCM 
(Garci a ‑Castro et al46; Rodri‑
guez ‑Garcia47; Coto48; 
Martin49)
Pt 74 MYBPC3 11:47359003 G C NM_000256.3a c.2541C>Ga Tyr847Tera Nonsense Het rs397515974 0 0 P, LP P PP3, PP5, PM1, 
PM2, PS1, PVS1
HCM Reported in individuals with 
HCM (Van Driest et al37; 
Berge et al40; Kapplinger 
et al41; Viswanathan et al42; 
Zhao et al43)
Pt 161 MYH7 14:23901922 C T NM_000257.3 c.428G>A Arg143Gln Missense Het rs397516209 0.0009 0.0004 LP P PP1, PP3, PM2, 
PM5, PS4
HCM Reported in association with 
HCM (Kimura et al50; Van 
Driest et al37; Song et al38; 
Coto et al48; Marsiglia et al51)
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The MYBPC3 c.2541C>G mutation was the only 
identified variant in cases 10, 74, and 3566, while 
it was associated with another sarcomeric alter‑
ation (ie, the MYH7 c.3116A>G,p.Glu1039Gly) 
in patient 22. The allele frequency of the MYH7 
c.3116A>G was very close to the 0.01% threshold, 
and we infer that this variant could be a modi‑
fier allele or a low penetrance variant contrib‑
uting to the severity of HCM expression in pa‑
tient 22. Among the 4 carriers of the MYBPC3 
c.2541C>G, patient 22 indeed manifested the ear‑
liest age at diagnosis, the need for septal myec‑
tomy at the age of 41 years, and the presence of 
a long QTc interval (FIGURE 1). The segregation of 
MYBPC3 c.2541C>G and of MYH7 c.3116A>G was 
tested in 4 relatives of case 22: a 50 ‑year ‑old sister 
affected by HCM and 3 children aged 9, 12, and 
16 years, who are currently asymptomatic. All of 
them were found to carry MYBPC3 c.2541C>G 
in heterozygosity, while they had the wild‑type 
MYH7 c.3116A variant (Supplementary materi‑
al, Figure S1A).
The MYBPC3 c.2541C>G variant was also de‑
tected in heterozygosity in a 19 ‑year ‑old daugh‑
ter of patient 74 (Supplementary material, Fig-
ure S1A). On clinical evaluation, she did not dis‑
play any chronic cardiac or noncardiac disease. 
Her echocardiogram showed normal left ven‑
tricular (left ventricular end ‑diastolic diameter, 
43 mm) and atrial size (left atrial appendage, 
17 cm2; right atrial appendage, 13.5 cm2), as well 
as normal thickness of intraventricular septum 
(end ‑diastolic diameter, 10 mm). Also, left ventric‑
ular systolic function was normal (70%), and she 
did not show any valvular abnormalities, signs of 
systolic anterior motion, or left ventricular out‑
flow obstruction. Therefore, at present, the chil‑
dren of case 22 and the daughter of case 74 are 
asymptomatic carriers of c.2541C>G and possi‑
bly would show later onset of the disease due to 
an age ‑related penetrance.
To investigate whether carriers of the MYBPC3 
c.2541C>G variant could share a common ances‑
tor, we performed a markers analysis. A haplo‑
type, spanning about 5 Mb, was found to segre‑
gate with the c.2541G variant allele in the family 
of patient 22. The alleles of the c.2541G ‑haplotype 
were also present in all the MYBPC3 c.2541C>G 
carriers (TABLE 2), even if we could not reconstruct 
their phase. This finding supports the hypothesis 
that the MYBPC3 c.2541C>G variant could have 
a founder role in the Polish population. In sup‑
port of this hypothesis, the MYBPC3 c.2541C>G 
variant has been recently found in another Polish 
patient with HCM, not related to any of the cas‑
es reported herein.25
Case 58 was found to carry the truncating 
CSRP3 c.364C>T (p.Arg122Ter) variant in ho‑
mozygosity (Supplementary material, Figure S1B), 
as confirmed by SYBR Green–based quantita‑
tive PCR  on ABI7900 HT Fast Real Time PCR 
System (ThermoFisher) (Supplementary mate‑
rial, Figure S1C). Patient 58 was a 56 ‑year ‑old 
woman diagnosed with HCM at the age of 54 TA
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11 beats). Family history was negative for HCM, 
but the CSRP3 c.364C>T variant was found to 
segregate in heterozygosity in a 29 ‑year ‑old son 
(Supplementary material, Figure S1B), who cur‑
rently does not suffer from any chronic cardi‑
ac or noncardiac diseases. He has no symptoms 
and is physically active. On echocardiography, he 
has normal left ventricular (left ventricular end‑
‑diastolic diameter, 46 mm) and atrial sizes (left 
atrial appendage, 17.5 cm2; right atrial append‑
age, 17 cm2). However, his intraventricular sep‑
tum was mildly thickened (end ‑diastolic diameter, 
13 mm), with normal systolic function (ejection 
due to early fatigue and chest pain. She main‑
ly complained of nonspecific and episodic chest 
pain (discomfort) on exertion. Echocardiogra‑
phy showed asymmetric interventricular septal 
hypertrophy (18 mm), posterior wall of 12 mm, 
ejection fraction of 70%, normal right ventricle, 
and maximal (provoked) left ventricular outflow 
tract gradient of 18 mm Hg without the systol‑
ic anterior motion of the mitral valve. Also, se‑
vere diastolic dysfunction with no signs of pul‑
monary hypertension was observed. The 24 ‑hour 
electrocardiogram highlighted 5 runs of nonsus‑
tained ventricular tachycardia (the longest one of 
TABLE 2 Haplotype analysis in cases carrying the MYBPC3 c.2541C>G variant
Marker Genomic position
start (Hg19)
c.2541G ‑haplotypea Pt 10 Pt 74 Daughter of Pt 74 Pt 3566
D11S1252 11:46446790 153* 153*‑153 153*‑153 153*‑153 153*‑161
MYBPC3 start 11:47353396
rs1052373 11:47354787 A* A*‑G A*‑G A*‑G A*‑G
c.2541C>G 11:47359003 G* G*‑C G*‑C G*‑C G*‑C
rs11570078 11:47365014 G* G*‑G G*‑A G*‑G G*‑G
rs2856650 11:47365199 C* C*‑T C*‑C C*‑T C*‑T
rs3729989 11:47370041 A* A*‑A A*‑G A*‑A A*‑A
rs11570051 11:47371442 T* T*‑C T*‑C T*‑C T*‑C
rs11570050 11:47371485 C* C*‑del C*‑C C*‑del C*‑del
MYBPC3 end 11:47374253
D11S4109 11:47601406 153* 153*‑167 153*‑171 153*‑165 153*‑167
D11SA1 11:47741121 257* 257*‑251 257*‑245 257*‑253 257*‑251
D11S1784 11:48022707 143* 143*‑141 143*‑149 143*‑141 143*‑145
D11S4165 11:50137951 217* 217*‑217 217*‑217 217*‑217 217*‑217
D11S1395 11:51382783 223* 223*‑223 223*‑231 223*‑227 223*‑227
a The c.2541G ‑haplotype was found by segregation analysis performed in patient 22 and her relatives.
Abbreviations: see TABLE 1
FIGURE 2 Penetrance 
of hypertrophic 
cardiomyopathy, 
according to age 
at diagnosis, in MYBPC3 
c.2541C>G carriers 
(blue) and in carriers of 
other DNA variants 
(green). Plot represents 
1 minus the probability of 
not having a diagnosis of 
hypertrophic 
cardiomyopathy (HCM) 
at each age. This 
probability is estimated 
by the Kaplan–Meier 
method. Patient 22 was 
not included in this 
analysis due to being 
a double‑variant carrier.
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and 4) myocardial biopsies of a HCM patient with 
a heterozygous CSRP3 missense variant showed 
myocyte disarray and a reduced level of MLP, 
suggesting that cardiomyopathy may stem from 
CSRP3 haploinsufficiency.27 To date, 24 carriers 
of a CSRP3 alteration were reported in the liter‑
ature or included in the ClinVar database: 18 had 
HCM and 6 were affected by dilated cardiomyop‑
athy. Among the HCM patients, 9 carried a het‑
erozygous CSRP3 variant (including 7 amino acid 
substitutions and 2 truncating variants), 2 cas‑
es were heterozygous but also carried a second 
variant in another gene, while 2 patients har‑
bored a truncating alteration in homozygosity 
(TABLE 3).11 Therefore, patient 58 described here‑
in is the third CSRP3 human knockout case re‑
ported so far. Our finding strengthens the as‑
sumption that at least several CSRP3 variants 
fraction, 67%), no valvular abnormalities, and no 
sign of systolic anterior motion and left ventric‑
ular outflow tract obstruction.
The CSRP3 c.364C>T (p.Arg122Ter) muta‑
tion is not a common variant since it is absent 
in GnomAD ‑Genomes and GnomAD ‑Exomes‑
‑European databases. In total, only 3 CSRP3 
c.364C>T alleles are listed in GnomAD ‑Exomes 
(ie, 2 in African and 1 in South Asian popula‑
tions), but never in a homozygous state. It has 
not been described in the literature before, but 
it is listed as likely pathogenic in the ClinVar da‑
tabase because of the following evidence: 1) it is 
a rare variant; 2) it is predicted to cause the loss 
of protein function either by protein truncation or 
nonsense ‑mediated mRNA decay; 3) CSRP3 ‑null 
mice develop cardiomyopathy and heart failure 
due to a disrupted cardiomyocyte architecture26; 
TABLE 3 CSRP3 variants to date reported in literature or listed in the ClinVar database (for references 51–67, see Supplementary material)
CSRP3 variant Zygosity Reference(s) Condition(s)
c.46A>T (p.Thr16Ser) Not reported ClinVar DCM
c.50insGCAGATTTCTT (p.Tyr18GlnfsX194) Het van Rijsingen et al60 HCM
c.96G>A (p.Lys32=) Not reported ClinVar DCM
c.122_123dupGG (p.Lys42Glyfs) Het Bos et al61 HCM
c.131T>C (p.Leu44Pro) Het Geier et al27; Geier et al62; 
ClinVar
Familial HCM 12, DCM 1M, not 
specified, cardiovascular 
phenotype
c.131T>C (p.Leu44Pro) Het, in association with MYBPC3 
p.Gly1041fs
Bos et al61 HCM
c.136A>C (p.Ser46Arg) Het, in association with TNNI3 
p.Arg162Gln
Bos et al61; ClinVar Familial HCM 12, DCM 1M, 
cardiomyopathy, not specified
c.160_164delTCGGAinsAGGGG 
(p.Ser54_Glu55delinsArgGly)
Het Geier et al27; ClinVar Familial HCM 12
c.172T>G (p.Cys58Gly) Het Geier et al62; ClinVar Familial HCM 12
c.190C>T (p.Arg64Cys) Het Bos et al61 HCM
c.197A>G (p.Tyr66Cys) Het Bos et a61 HCM
c.206A>G (p.Lys69Arg) Not reported ClinVar Familial HCM 12, DCM 1M, not 
specified, cardiovascular 
phenotype
c.214G>A (p.Gly72Arg) Het Hershberger et al63 DCM
c.233G>T (p.Gly78Val) Not reported ClinVar Cardiovascular phenotype, DCM
c.272A>T (p.Gln91Leu) Het Bos et al61 HCM
c.299G>A (p.Arg100His) Het Andersen et al64 HCM
c.336G>A (p.Ala112=) Not reported ClinVar Not specified, HCM, 
cardiovascular phenotype, DCM, 
DCM, dominant
c.354G>A (p.Glu118=) Not reported ClinVar DCM
c.364C>T (p.Arg122Ter) Hom This report HCM
c.365G>A (p.Arg122Gln) Not reported ClinVar Familial HCM 12, DCM 1M, 
cardiomyopathy
c.369T>A (p.Cys123Ter) Hom Janin et al11 HCM
c.420G>C (p.Trp140Cys) Not reported ClinVar DCM
c.449G>A (p.Cys150Tyr) Not reported ClinVar Familial HCM 12, DCM 1M, not 
specified, cardiovascular 
phenotype
c.483dup (p.Lys162GlnfsX52) Hom Janin et al11 Hypertrophic cardiomyopathy
c.536C>T (p.Thr179Met) Not reported ClinVar Familial HCM 12, DCM 1M, not 
specified
Abbreviations: DCM, dilated cardiomyopathy; others, see TABLE 1
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TABLE 4 Secondary molecular findings (for references 51–67, see Supplementary material)
Patient Gene Location Ref Alt RefSeq Nucleotide AA Coding 
impact
Zygosity dbSNP GnomAD ‑Exomes 
allele frequency (%)
ClinVar ACMG / AMP 2015 ClinVar conditions Comment
European 
Non ‑Finnish
Total Classification Activated 
rules
Pt 64 PMM2 16:8941632 G A NM_000303.2 c.691G>A Val231Met Missense Het rs80338707 0.011 0.007 P VUS ‑3B PP3, PP5, 
PM1
Carbohydrate ‑deficient 
glycoprotein syndrome 
type Ia
Reported in several individuals 
affected with PMM2 ‑CDG 
(Barone et al65)
Pt 161 SCO2 22:50962423 C T NM_005138.2 c.418G>A Glu140Lys Missense Het rs74315511 0.017 0.008 P VUS ‑3B PP3, PP5, 
PM1
Cardioencephalomyo‑ 
pathy, fatal infantile, due 
to cytochrome c 
oxidase deficiency 1a
Myopia 6
Previously reported as 
c.1541G>A in homozygosity or 
compound heterozygosity with 
a second SCO2 variant in 
individuals with SCO2 ‑related 
clinical features including HCM 
(Papadopoulou et al32; Jaksch 
et al31)
Reported as a heterozygous 
mutation in 1 individual with 
autosomal dominant high ‑grade 
myopia (Tran ‑Viet et al33)
Pt 211 GUSB 7:65444841 C T NM_000181.3 c.454G>A Asp152Asn Missense Het rs149606212 0.189 0.113 VUS LP PP3, PM1, 
PM2
MPS type VIIa Identified in homozygosity in 
a child with MPS type VIIa 
(Vervoort et al66). Transfection 
studies showed that the D152N 
substitution resulted in decreased 
enzyme activity. Vervoort et al66 
referred to D152N as 
a “pseudodeficiency allele” that 
leads to greatly reduced levels of 
beta ‑glucuronidase activity 
without apparent deleterious 
consequences.
Pt 218 GYG1 3:148714249 G C NM_004130.3 c.304G>C Asp102His Missense Het rs143137713 0.189 0.102 P/LP VUS ‑3B PP3, PP5, 
PM1
Glycogen storage 
disease XVa
Reported in homozygosity or 
compound heterozygosity in 
individuals with glycogenin‑1 
deficiency (Malfatti et al67; 
Hedberg ‑Oldfors et al29)
a   Autosomal recessive
Abbreviations: MPS, mucopolysaccharidosis; others, see TABLE 1
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lead to HCM with an autosomal recessive inher‑
itance11 rather than with an autosomal dominant 
transmission as recorded in the Online Mendelian 
Inheritance in Man (OMIM) database (OMIM: 
*600824). The mouse model knock ‑in for CSRP3 
pathogenic variants also corroborates the hypoth‑
esis of autosomal recessive inheritance of the car‑
diac disease and recalls the findings displayed by 
patient 58 and his son.28 Indeed, the heterozygous 
mice for CSRP3 pathogenic variants do not dis‑
play an overt cardiac phenotype (except for an in‑
crease in anterior wall thickness), while the ho‑
mozygous mutated mouse shows a clear cardio‑
myopathy phenotype.28
The “non –core HCM genes” with mutations in 
the present HCM cohort were GYG1, GUSB, PMM2 
and SCO2. Cases 64, 161, 211, and 218 were in‑
deed identified as heterozygous carriers of autoso‑
mal recessive alterations associated with PMM2, 
SCO2, GUSB, and GYG1 deficiency, respectively 
(TABLE 4). The GYG1, GUSB, PMM2, and SCO2 vari‑
ants were prioritized by the TGex software since 
they were related to the cardiomyopathy pheno‑
type: GYG1 c.304G>C, found in patient 218, has 
previously been described in homozygosity in 
cases affected by severe cardiomyopathy with‑
out skeletal muscle weakness29; the GUSB and 
PMM2 genes are responsible for genetic disor‑
ders associated with HCM30; the SCO2 c.418G>A 
variant has been previously reported by the name 
of “c.1541G>A” in homozygosity or in compound 
heterozygosity in individuals with SCO2 ‑related 
clinical features including HCM.31,32 Therefore, 
these results can be considered “secondary find‑
ings” for which we cannot exclude a possible hy‑
pomorphic impact over the patients’ phenotype. 
Also, the SCO2 p.Glu140Lys variant was previ‑
ously associated with autosomal dominant high‑
‑grade myopia.33 In the present patient, present‑
ing low myopia of –2.00 diopters in both eyes, 
the SCO2 c.418G>A variant exhibited reduced 
penetrance.
In conclusion, this report expands the mutation‑
al spectrum and the inheritance pattern of HCM. 
The ultra ‑rare MYBPC3 c.2541C>G (p.Tyr847Ter) 
alteration, found in 9 cases (of which 4 were index 
patients), while absent in databases from large‑
‑scale sequencing projects, acts as a variant hotspot 
in the present Polish cohort and correlates with 
a younger age at HCM diagnosis. These findings, if 
confirmed in a wider population of the same eth‑
nic origin, will increase the number of truncating 
founder MYBPC3 alterations.
The identification of the novel homozygous 
null CSRP3 variant leading to HCM suggests that 
the autosomal recessive inheritance pattern could 
be more frequent in HCM than reported so far. 
In heterozygosity, the null CSRP3 allele seems to 
correlate only with a mild thickening of the intra‑
ventricular septum.
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